{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:37Z","timestamp":1792166317446,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of response to ICI is of crucial importance. Circulating extracellular vesicles (EVs) such as PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EV mediate resistance to anti-PD1, instead the role of PD1\n                      <jats:sup>+<\/jats:sup>\n                      EV is not fully understood.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We isolated the circulating EVs from the plasma of an observational cohort study of 71 metastatic melanoma patients and correlated the amount of PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EVs and PD1\n                      <jats:sup>+\u00a0<\/jats:sup>\n                      EVs\u00a0with the response to ICI. The analysis was performed according to the origin of EVs from the tumor and the immune cells. Subsequently, we analysed the data in a validation cohort of 22 MM patients to assess the reliability of identified EV-based biomarkers. Additionally we assessed the involvement of PD1\n                      <jats:sup>+<\/jats:sup>\n                      EVs in the seizure of nivolumab and in the perturbation of immune cells-mediated killing of melanoma spheroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The level of PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EVs released from melanoma and CD8\n                      <jats:sup>+\u00a0<\/jats:sup>\n                      T\u00a0cells and that of PD1\n                      <jats:sup>+<\/jats:sup>\n                      EVs irrespective of the cellular origin were higher in non-responders. The Kaplan-Meier curves indicated that higher levels of PD1+ EVs were significantly correlated with poorer progression-free survival (PFS) and overall survival (OS). Significant correlations were found for PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EVs only when released from melanoma and T cells. The multivariate analysis showed that high level of PD1\n                      <jats:sup>+<\/jats:sup>\n                      EVs, from T cells and B cells, and high level of PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EVs from melanoma cells, are independent biomarkers of response. The reliability of PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EVs from melanoma and PD1\n                      <jats:sup>+<\/jats:sup>\n                      EVs from T cells in predicting PFS was confirmed in the validation cohort through the univariate Cox-hazard regression analysis. Moreover we discovered that the circulating EVs captured nivolumab and reduced the T cells trafficking and tumor spheroids killing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our study identified circulating PD1\n                      <jats:sup>+<\/jats:sup>\n                      EVs as driver of resistance to anti-PD1, and highlighted that the analysis of single EV population by liquid biopsy is a promising tool to stratify MM patients for immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-021-01490-9","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:17:53Z","timestamp":1642479473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Simona","family":"Serrat\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Fonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"De Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Iacobazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"De Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Paradiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-5049","authenticated-orcid":false,"given":"Amalia","family":"Azzariti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12885-018-4479-2","volume":"18","author":"M Guida","year":"2018","unstructured":"Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, et al. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer. 2018;18:552.","journal-title":"BMC Cancer"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141\u201356.","journal-title":"Pathology."},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189\u201399.","journal-title":"N Engl J Med"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ajd.13498","volume":"62","author":"M Giavina-Bianchi","year":"2021","unstructured":"Giavina-Bianchi M, Nacagamo Sotto M, Giavina-Bianchi P, Munhoz R, Festa Neto C, Kalil J. Inter- and intra-patient heterogeneity of PD-L1 expression in metastatic melanomas: a retrospective study. Australas J Dermatol. 2021;62:227\u20139.","journal-title":"Australas J Dermatol"},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3390\/cancers13092041","volume":"13","author":"EK Vetsika","year":"2021","unstructured":"Vetsika EK, Sharma P, Samaras I, Markou A, Georgoulias V, Whiteside TL, et al. Small extracellular vesicles in pre-therapy plasma predict clinical outcome in non-small-cell lung cancer patients. Cancers. 2021;13:2041.","journal-title":"Cancers."},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/cells10020212","volume":"10","author":"C Keup","year":"2021","unstructured":"Keup C, Suryaprakash V, Storbeck M, Hoffmann O, Kimmig R, Kasimir-Bauer S. Longitudinal multi-parametric liquid biopsy approach identifies unique features of circulating tumor cell, extracellular vesicle, and cell-free DNA characterization for disease monitoring in metastatic breast cancer patients. Cells. 2021;10:212.","journal-title":"Cells."},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"1438720","DOI":"10.1080\/20013078.2018.1438720","volume":"7","author":"S Roy","year":"2018","unstructured":"Roy S, Hochberg FH, Jones PS. Extracellular vesicles: the growth as diagnostics and therapeutics; a survey. J Extracell Vesicles. 2018;7:1438720.","journal-title":"J Extracell Vesicles"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G Van Niel","year":"2018","unstructured":"Van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri3622","volume":"14","author":"PD Robbins","year":"2014","unstructured":"Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14:195\u2013208.","journal-title":"Nat Rev Immunol"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.canlet.2020.04.009","volume":"482","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Padmakumar S, Amiji MM. Extracellular vesicle-mediated nucleic acid transfer and reprogramming in the tumor microenvironment. Cancer Lett. 2020;482:33\u201343.","journal-title":"Cancer Lett"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123696","volume":"12","author":"KHW Yim","year":"2020","unstructured":"Yim KHW, Al HA, Borgoni S, Chahwan R. Extracellular vesicles orchestrate immune and tumor interaction networks. Cancers. 2020;12:1\u201323.","journal-title":"Cancers."},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-019-0973-7","volume":"18","author":"X Bian","year":"2019","unstructured":"Bian X, Xiao YT, Wu T, Yao M, Du L, Ren S, et al. Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. Mol Cancer. 2019;18:50.","journal-title":"Mol Cancer"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3390\/ijms22073374","volume":"22","author":"S Lipinski","year":"2021","unstructured":"Lipinski S, Tiemann K. Extracellular vesicles and their role in the spatial and temporal expansion of tumor\u2013immune interactions. Int J Mol Sci. 2021;22:3374.","journal-title":"Int J Mol Sci"},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"e001698","DOI":"10.1136\/jitc-2020-001698","volume":"9","author":"Z Yin","year":"2021","unstructured":"Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, et al. Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J ImmunoTher Cancer. 2021;9:e001698.","journal-title":"J ImmunoTher Cancer"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.tranon.2021.101047","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang J, Zeng H, Zhang H, Han Y. The role of exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021;14:101047.","journal-title":"Transl Oncol"},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41598-019-56542-4","volume":"10","author":"P Sharma","year":"2020","unstructured":"Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020;10:92.","journal-title":"Sci Rep"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/ijms21010052","volume":"21","author":"F Mannavola","year":"2020","unstructured":"Mannavola F, D\u2019oronzo S, Cives M, Stucci LS, Ranieri G, Silvestris F, et al. Extracellular vesicles and epigenetic modifications are hallmarks of melanoma progression. Int J Mol Sci. 2020;21:52.","journal-title":"Int J Mol Sci"},{"key":"1490_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123563","volume":"12","author":"S Mittal","year":"2020","unstructured":"Mittal S, Gupta P, Chaluvally-Raghavan P, Pradeep S. Emerging role of extracellular vesicles in immune regulation and cancer progression. Cancers. 2020;12:1\u201316.","journal-title":"Cancers."},{"key":"1490_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/ijbs.27796","volume":"15","author":"T Huang","year":"2019","unstructured":"Huang T, Deng CX. Current progresses of exosomes as cancer diagnostic and prognostic biomarkers. Int J Biol Sci. 2019;15:1\u201311.","journal-title":"Int J Biol Sci"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102825","volume":"12","author":"M Mathew","year":"2020","unstructured":"Mathew M, Zade M, Mezghani N, Patel R, Wang Y, Momen-Heravi F. Extracellular vesicles as biomarkers in cancer immunotherapy. Cancers. 2020;12:1\u201321.","journal-title":"Cancers."},{"key":"1490_CR23","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.3390\/ijms22126234","volume":"22","author":"TL Whiteside","year":"2021","unstructured":"Whiteside TL, Diergaarde B, Hong CS. Tumor-derived exosomes (Tex) and their role in immuno-oncology. Int J Mol Sci. 2021;22:6234.","journal-title":"Int J Mol Sci"},{"key":"1490_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382\u20136.","journal-title":"Nature."},{"key":"1490_CR25","doi-asserted-by":"publisher","first-page":"e002372","DOI":"10.1136\/jitc-2021-002372","volume":"9","author":"L Porcelli","year":"2021","unstructured":"Porcelli L, Guida M, De Summa S, Di Fonte R, De Risi I, Garofoli M, et al. UPAR + extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. J ImmunoTher Cancer. 2021;9:e002372.","journal-title":"J ImmunoTher Cancer"},{"key":"1490_CR26","doi-asserted-by":"publisher","first-page":"1926762","DOI":"10.1080\/2162402X.2021.1926762","volume":"10","author":"D Machiraju","year":"2021","unstructured":"Machiraju D, Wiecken M, Lang N, H\u00fclsmeyer I, Roth J, Schank TE, et al. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients. OncoImmunology. 2021;10:1926762.","journal-title":"OncoImmunology."},{"key":"1490_CR27","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352.","journal-title":"Lancet Oncol"},{"key":"1490_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1538-7836.2011.04610.x","volume":"10","author":"R Lacroix","year":"2012","unstructured":"Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost. 2012;10:437\u201346.","journal-title":"J Thromb Haemost"},{"key":"1490_CR29","doi-asserted-by":"publisher","first-page":"108319","DOI":"10.1016\/j.clim.2019.108319","volume":"211","author":"A Vecchione","year":"2020","unstructured":"Vecchione A, Di Fonte R, Gerosa J, Jofra T, Cicalese MP, Napoleone V, et al. Reduced PD-1 expression on circulating follicular and conventional FOXP3+ Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children. Clin Immunol. 2020;211:108319.","journal-title":"Clin Immunol"},{"key":"1490_CR30","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.","journal-title":"J Extracell Vesicles"},{"key":"1490_CR31","doi-asserted-by":"publisher","first-page":"Unit 3.22","DOI":"10.1002\/0471143030.cb0322s30","volume":"30","author":"C Th\u00e9ry","year":"2006","unstructured":"Th\u00e9ry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;30:Unit 3.22.","journal-title":"Curr Protoc Cell Biol"},{"key":"1490_CR32","doi-asserted-by":"crossref","unstructured":"Biagioni A, Laurenzana A, Menicacci B, Peppicelli S, Andreucci E, Bianchini F, et al. uPAR-expressing melanoma exosomes promote angiogenesis by VE-cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells. Cell Mol Life Sci. 2020;78(6):3057-72.","DOI":"10.1007\/s00018-020-03707-4"},{"key":"1490_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/10717544.2020.1869866","volume":"28","author":"JY Wu","year":"2021","unstructured":"Wu JY, Li YJ, Bin HX, Huang S, Xiang DX. Preservation of small extracellular vesicles for functional analysis and therapeutic applications: a comparative evaluation of storage conditions. Drug Deliv. 2021;28:162\u201370.","journal-title":"Drug Deliv"},{"key":"1490_CR34","doi-asserted-by":"publisher","first-page":"1596016","DOI":"10.1080\/20013078.2019.1596016","volume":"8","author":"D Bachurski","year":"2019","unstructured":"Bachurski D, Schuldner M, Nguyen PH, Malz A, Reiners KS, Grenzi PC, et al. Extracellular vesicle measurements with nanoparticle tracking analysis\u2013an accuracy and repeatability comparison between NanoSight NS300 and ZetaView. J Extracell Vesicles. 2019;8:1596016.","journal-title":"J Extracell Vesicles"},{"key":"1490_CR35","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1002\/cpsc.76","volume":"48","author":"C Gorgun","year":"2019","unstructured":"Gorgun C, Reverberi D, Rotta G, Villa F, Quarto R, Tasso R. Isolation and flow cytometry characterization of extracellular-vesicle subpopulations derived from human mesenchymal stromal cells. Curr Protoc Stem Cell Biol. 2019;48:e76.","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"1490_CR36","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/cancers13102505","volume":"13","author":"S Serrat\u00ec","year":"2021","unstructured":"Serrat\u00ec S, Porcelli L, Fragassi F, Garofoli M, Di Fonte R, Fucci L, et al. The interaction between reactive peritoneal mesothelial cells and tumor cells via extracellular vesicles facilitates colorectal cancer dissemination. Cancers. 2021;13:2505.","journal-title":"Cancers."},{"key":"1490_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/ol.2020.11940","volume":"20","author":"Q Shao","year":"2020","unstructured":"Shao Q, Deng L, Liu H, Liu Z, Chen J, Jiang F, et al. Involvement of MM cell-derived exosomes in T lymphocytes immune responses. Oncol Lett. 2020;20:31.","journal-title":"Oncol Lett"},{"key":"1490_CR38","doi-asserted-by":"publisher","first-page":"1800430","DOI":"10.1002\/biot.201800430","volume":"14","author":"K Kalishwaralal","year":"2019","unstructured":"Kalishwaralal K, Kwon WY, Park KS. Exosomes for non-invasive cancer monitoring. Biotechnol J. 2019;14:1800430.","journal-title":"Biotechnol J"},{"key":"1490_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-7253-1_12","volume":"1660","author":"EJK Kowal","year":"2017","unstructured":"Kowal EJK, Ter-Ovanesyan D, Regev A, Church GM. Extracellular vesicle isolation and analysis by Western blotting. Methods Mol Biol. 2017;1660:143\u201352.","journal-title":"Methods Mol Biol"},{"key":"1490_CR40","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11:4835.","journal-title":"Nat Commun"},{"key":"1490_CR41","doi-asserted-by":"crossref","unstructured":"Sun X, Zhang T, Li M, Yin L, Xue J. Immunosuppressive B cells expressing PD-1\/PD-L1 in solid tumors: a mini review. QJM. 2019. hcz162.","DOI":"10.1093\/qjmed\/hcz162"},{"key":"1490_CR42","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1038\/s41467-018-05047-1","volume":"9","author":"L Brochez","year":"2018","unstructured":"Brochez L, Meireson A, Chevolet I, Sundahl N, Ost P, Kruse V. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nat Commun. 2018;9:2921.","journal-title":"Nat Commun"},{"key":"1490_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.abb.2014.06.018","volume":"563","author":"A Nosrati","year":"2014","unstructured":"Nosrati A, Wei ML. Sex disparities in melanoma outcomes: the role of biology. Arch Biochem Biophys. 2014;563:42\u201350.","journal-title":"Arch Biochem Biophys"},{"key":"1490_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020168","volume":"13","author":"G Awada","year":"2021","unstructured":"Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, et al. A comprehensive analysis of baseline clinical characteristics and biomarkers associated with outcome in advanced melanoma patients treated with pembrolizumab. Cancers. 2021;13:1\u201318.","journal-title":"Cancers."},{"key":"1490_CR45","doi-asserted-by":"publisher","unstructured":"Pretti MAM, Bernardes SS, da Cruz JGV, Boroni M, Possik PA. Extracellular vesicle-mediated crosstalk between melanoma and the immune system: impact on tumor progression and therapy response. J Leukoc Biol. 2020. https:\/\/doi.org\/10.1002\/JLB.3MR0320-644R.","DOI":"10.1002\/JLB.3MR0320-644R"},{"key":"1490_CR46","doi-asserted-by":"publisher","first-page":"103365","DOI":"10.1016\/j.ebiom.2021.103365","volume":"67","author":"E Zhou","year":"2021","unstructured":"Zhou E, Li Y, Wu F, Guo M, Xu J, Wang S, et al. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine. 2021;67:103365.","journal-title":"EBioMedicine."},{"key":"1490_CR47","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, et al. Exosomal PD-L1 harbors active defense function to suppress t cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28:862\u20134.","journal-title":"Cell Res"},{"key":"1490_CR48","doi-asserted-by":"publisher","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","volume":"9","author":"M Cordonnier","year":"2020","unstructured":"Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles. 2020;9:1710899.","journal-title":"J Extracell Vesicles"},{"key":"1490_CR49","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/bjd.18379","volume":"182","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Schr\u00f6ter U, H\u00f6xtermann S, Susok L, Stockfleth E, Becker JC. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade. Br J Dermatol. 2020;182:1214\u201320.","journal-title":"Br J Dermatol"},{"key":"1490_CR50","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.","journal-title":"Front Immunol"},{"key":"1490_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.annonc.2019.09.005","volume":"31","author":"S Ugurel","year":"2020","unstructured":"Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, et al. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. Ann Oncol. 2020;31:144\u201352.","journal-title":"Ann Oncol"},{"key":"1490_CR52","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1 \u00fe exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24:896\u2013905.","journal-title":"Clin Cancer Res"},{"key":"1490_CR53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12967-019-2101-2","volume":"17","author":"C Li","year":"2019","unstructured":"Li C, Li C, Zhi C, Liang W, Wang X, Chen X, et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J Transl Med. 2019;17:355.","journal-title":"J Transl Med"},{"key":"1490_CR54","first-page":"280","volume":"4","author":"G Brock","year":"2015","unstructured":"Brock G, Castellanos-Rizaldos E, Hu L, Coticchia C, Skog J. Liquid biopsy for cancer screening, patient stratification and monitoring. Transl Cancer Res. 2015;4:280\u201390.","journal-title":"Transl Cancer Res"},{"key":"1490_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nmeth.4185","volume":"14","author":"J Van Deun","year":"2017","unstructured":"Van Deun J, Mestdagh P, Agostinis P, Akay \u00d6, Anand S, Anckaert J, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods. 2017;14:228\u201332.","journal-title":"Nat Methods"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-021-01490-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T06:07:16Z","timestamp":1666418836000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01490-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01490-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was previously approved by the ethics committee of the IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy, (Prot. 590\/16 C.E.) and written informed consent was obtained from all the patients enrolled in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}